Stock Traders Buy Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) saw some unusual options trading on Friday. Stock traders bought 32,948 call options on the stock. This represents an increase of 1,371% compared to the typical volume of 2,240 call options.

Insider Activity

In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,942,629 shares of company stock worth $23,071,486. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in shares of Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after acquiring an additional 2,593,910 shares during the period. Rubric Capital Management LP lifted its position in Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares during the last quarter. State Street Corp boosted its stake in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after purchasing an additional 1,118,561 shares during the period. Geode Capital Management LLC grew its position in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. Finally, DME Capital Management LP increased its stake in shares of Roivant Sciences by 14.8% in the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after purchasing an additional 620,470 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 2.4 %

Shares of Roivant Sciences stock opened at $11.15 on Friday. The stock has a market capitalization of $8.12 billion, a price-to-earnings ratio of 1.97 and a beta of 1.27. Roivant Sciences has a twelve month low of $9.69 and a twelve month high of $13.06. The business’s 50 day simple moving average is $11.79 and its 200-day simple moving average is $11.58.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.